668 related articles for article (PubMed ID: 25920087)
1. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.
Beuers U; Trauner M; Jansen P; Poupon R
J Hepatol; 2015 Apr; 62(1 Suppl):S25-37. PubMed ID: 25920087
[TBL] [Abstract][Full Text] [Related]
2. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
3. New therapies target the toxic consequences of cholestatic liver disease.
Jansen PLM
Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):277-285. PubMed ID: 29310470
[TBL] [Abstract][Full Text] [Related]
4. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of primary sclerosing cholangitis: a role for novel bile acids and other (post-)transcriptional modulators?
Beuers U; Kullak-Ublick GA; Pusl T; Rauws ER; Rust C
Clin Rev Allergy Immunol; 2009 Feb; 36(1):52-61. PubMed ID: 18751930
[TBL] [Abstract][Full Text] [Related]
6. Nuclear receptors CAR and PXR; therapeutic targets for cholestatic liver disease.
Kakizaki S; Takizawa D; Tojima H; Horiguchi N; Yamazaki Y; Mori M
Front Biosci (Landmark Ed); 2011 Jun; 16(8):2988-3005. PubMed ID: 21622216
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
8. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
9. Drug insight: Mechanisms and sites of action of ursodeoxycholic acid in cholestasis.
Beuers U
Nat Clin Pract Gastroenterol Hepatol; 2006 Jun; 3(6):318-28. PubMed ID: 16741551
[TBL] [Abstract][Full Text] [Related]
10. Fibrates and cholestasis.
Ghonem NS; Assis DN; Boyer JL
Hepatology; 2015 Aug; 62(2):635-43. PubMed ID: 25678132
[TBL] [Abstract][Full Text] [Related]
11. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
12. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia.
Chen HL; Liu YJ; Chen HL; Wu SH; Ni YH; Ho MC; Lai HS; Hsu WM; Hsu HY; Tseng HC; Jeng YM; Chang MH
Pediatr Res; 2008 Jun; 63(6):667-73. PubMed ID: 18327154
[TBL] [Abstract][Full Text] [Related]
13. Targeting FXR in Cholestasis.
Keitel V; Dröge C; Häussinger D
Handb Exp Pharmacol; 2019; 256():299-324. PubMed ID: 31201556
[TBL] [Abstract][Full Text] [Related]
14. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies.
Trauner M; Halilbasic E; Kazemi-Shirazi L; Kienbacher C; Staufer K; Traussnigg S; Hofer H
Dig Dis; 2014; 32(5):631-6. PubMed ID: 25034298
[TBL] [Abstract][Full Text] [Related]
16. Role of farnesoid X receptor in cholestasis.
Yuan ZQ; Li KW
J Dig Dis; 2016 Aug; 17(8):501-509. PubMed ID: 27383832
[TBL] [Abstract][Full Text] [Related]
17. Gluco-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology.
Brønden A; Knop FK
J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31630179
[TBL] [Abstract][Full Text] [Related]
18. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Silveira MG; Lindor KD
Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
[TBL] [Abstract][Full Text] [Related]
19. Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver.
Zollner G; Wagner M; Fickert P; Geier A; Fuchsbichler A; Silbert D; Gumhold J; Zatloukal K; Kaser A; Tilg H; Denk H; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2005 Nov; 289(5):G798-805. PubMed ID: 16002565
[TBL] [Abstract][Full Text] [Related]
20. Targeting FXR in cholestasis: hype or hope.
Fiorucci S; Distrutti E; Ricci P; Giuliano V; Donini A; Baldelli F
Expert Opin Ther Targets; 2014 Dec; 18(12):1449-59. PubMed ID: 25200104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]